Experience EyeArt

Immediate, Fully-automated, On-site Diabetic Retinopathy Screening

EyeArt_Mac_Macbook_Mockups_img_withCEmark

* Products were supported by Award numbers R44EB013585, R42TR000377, R44TR000377, R43EY024848, R43EY025984, SB1EY027241, and R43EY028081  from the National Institutes of Health (NIH). The content is solely the responsibility of Eyenuk, Inc. and does not necessarily represent the official views of NIH.

** The devices are covered by one or more of the following US patents and their foreign counterparts: 8879813, 8885901, 9002085, and 9008391. Additional patents are pending.

EyeArt™ has been cleared for sales as a Class IIa medical device by EU and as a Class 2 medical device by Health Canada.

In the United States, EyeArt™ is limited by federal law to investigational use only and is not available for sale.

EyeMark™, EyeApp™, EyeSeeAMD™,  EyeSeeGlaucoma™ have not yet been cleared for sales in any region.